drugset / Trial / NCT04405154
A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to determine the efficacy and safety of camrelizumab given concomitantly with chemoradiation in participants with unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in addition to chemoradiation, the standard treatment for LA-HNSCC.
Timeline
- Start
- 2020-06-01
- Primary completion
- 2023-05-31
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |